Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy

For metastatic NSCLC (mNSCLC) patients (pts) with oncogenic driver (EGFR mutation or ALK/ROS translocation), progressing after tyrosine kinase inhibitors (TKI), it is recommended to try to obtain a new mutational profile by associating liquid and tumor rebiopsy, according to local conditions and clinical modalities of progression. The objective of this study is to analyze the practices in terms of tissue and blood rebiopsies in mNSCLC EGFR/ALK/ROS pts progressing after TKI before their inclusion in a phase II trial (GFPC 06-2018) testing the effectiveness of immunotherapy-platin-based-chemotherapy combinations.